Lower RPS14 expression in MDS patients without 5q deletion was reported to be associated with increased apoptosis of nucleated erythrocytes; consequently, an up-regulation during treatment could be a positively predictor marker of response to lenalidomide [45]. The gene discussed is RPS14; the disease is myelodysplastic syndrome.